Establishment Labs to Present at Citi’s 2025 Unplugged Medtech and Life Sciences Access Day
Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company focused on women's health and wellness in breast aesthetics and reconstruction, has announced its participation in Citi's 2025 Unplugged Medtech and Life Sciences Access Day. The company's leadership team, including CEO Juan José Chacón-Quirós, President Peter Caldini, and CFO Raj Denhoy, will present on February 27, 2025, at 8:00 a.m. ET.
The company has delivered over four million Motiva® devices to surgeons since 2010 and operates in more than 90 countries. Their product portfolio includes innovative solutions such as Mia Femtech®, Preservé™, GEM®, Motiva Flora® tissue expander, and Zensor™ RFID technology platform. These solutions are backed by over 200 patent applications and more than 100 scientific studies. Manufacturing takes place at two Costa Rica facilities compliant with ISO13485:2024 and FDA standards.
Establishment Labs Holdings Inc. (NASDAQ: ESTA), un'azienda globale di tecnologia medica focalizzata sulla salute e il benessere delle donne nell'estetica e nella ricostruzione mammaria, ha annunciato la sua partecipazione al Citi's 2025 Unplugged Medtech and Life Sciences Access Day. Il team dirigenziale dell'azienda, incluso il CEO Juan José Chacón-Quirós, il Presidente Peter Caldini e il CFO Raj Denhoy, presenterà il 27 febbraio 2025, alle 8:00 a.m. ET.
L'azienda ha fornito oltre quattro milioni di dispositivi Motiva® ai chirurghi dal 2010 e opera in più di 90 paesi. Il loro portafoglio di prodotti include soluzioni innovative come Mia Femtech®, Preservé™, GEM®, Motiva Flora® espansore tissutale e la piattaforma tecnologica Zensor™ RFID. Queste soluzioni sono supportate da oltre 200 domande di brevetto e più di 100 studi scientifici. La produzione avviene in due stabilimenti in Costa Rica conformi agli standard ISO13485:2024 e FDA.
Establishment Labs Holdings Inc. (NASDAQ: ESTA), una empresa global de tecnología médica centrada en la salud y el bienestar de las mujeres en estética y reconstrucción mamaria, ha anunciado su participación en el Día de Acceso a Medtech y Ciencias de la Vida 2025 de Citi. El equipo directivo de la empresa, que incluye al CEO Juan José Chacón-Quirós, al Presidente Peter Caldini y al CFO Raj Denhoy, presentará el 27 de febrero de 2025, a las 8:00 a.m. ET.
La empresa ha entregado más de cuatro millones de dispositivos Motiva® a cirujanos desde 2010 y opera en más de 90 países. Su cartera de productos incluye soluciones innovadoras como Mia Femtech®, Preservé™, GEM®, Motiva Flora® expansor de tejido y la plataforma tecnológica Zensor™ RFID. Estas soluciones están respaldadas por más de 200 solicitudes de patentes y más de 100 estudios científicos. La fabricación se lleva a cabo en dos instalaciones en Costa Rica que cumplen con los estándares ISO13485:2024 y FDA.
Establishment Labs Holdings Inc. (NASDAQ: ESTA)는 여성의 건강과 웰빙에 중점을 둔 글로벌 의료 기술 회사로, 유방 미용 및 재건 분야에서 활동하고 있습니다. 이 회사는 Citi의 2025 Unplugged Medtech and Life Sciences Access Day에 참여한다고 발표했습니다. CEO Juan José Chacón-Quirós, 사장 Peter Caldini, CFO Raj Denhoy를 포함한 경영진 팀이 2025년 2월 27일 오전 8시(ET)에 발표할 예정입니다.
이 회사는 2010년 이후로 외과의사에게 400만 개 이상의 Motiva® 장치를 공급했으며, 90개국 이상에서 운영되고 있습니다. 그들의 제품 포트폴리오에는 Mia Femtech®, Preservé™, GEM®, Motiva Flora® 조직 확장기 및 Zensor™ RFID 기술 플랫폼과 같은 혁신적인 솔루션이 포함되어 있습니다. 이러한 솔루션은 200건 이상의 특허 출원 및 100건 이상의 과학 연구에 의해 뒷받침됩니다. 제조는 ISO13485:2024 및 FDA 기준을 준수하는 코스타리카의 두 시설에서 이루어집니다.
Establishment Labs Holdings Inc. (NASDAQ: ESTA), une entreprise mondiale de technologie médicale axée sur la santé et le bien-être des femmes dans l'esthétique et la reconstruction mammaire, a annoncé sa participation à la Journée d'Accès Medtech et Sciences de la Vie 2025 de Citi. L'équipe de direction de l'entreprise, comprenant le PDG Juan José Chacón-Quirós, le Président Peter Caldini et le CFO Raj Denhoy, fera une présentation le 27 février 2025 à 8h00 ET.
L'entreprise a livré plus de quatre millions de dispositifs Motiva® aux chirurgiens depuis 2010 et opère dans plus de 90 pays. Leur portefeuille de produits comprend des solutions innovantes telles que Mia Femtech®, Preservé™, GEM®, Motiva Flora® expanseur de tissu et la plateforme technologique Zensor™ RFID. Ces solutions sont soutenues par plus de 200 demandes de brevet et plus de 100 études scientifiques. La fabrication a lieu dans deux installations au Costa Rica conformes aux normes ISO13485:2024 et FDA.
Establishment Labs Holdings Inc. (NASDAQ: ESTA), ein globales Medizintechnikunternehmen, das sich auf die Gesundheit und das Wohlbefinden von Frauen im Bereich der Brustästhetik und -rekonstruktion konzentriert, hat seine Teilnahme am Citi's 2025 Unplugged Medtech and Life Sciences Access Day bekannt gegeben. Das Führungsteam des Unternehmens, einschließlich CEO Juan José Chacón-Quirós, Präsident Peter Caldini und CFO Raj Denhoy, wird am 27. Februar 2025 um 8:00 Uhr ET präsentieren.
Das Unternehmen hat seit 2010 über vier Millionen Motiva®-Geräte an Chirurgen geliefert und ist in mehr als 90 Ländern tätig. Ihr Produktportfolio umfasst innovative Lösungen wie Mia Femtech®, Preservé™, GEM®, Motiva Flora® Gewebeexpander und die Zensor™ RFID-Technologieplattform. Diese Lösungen werden durch über 200 Patentanmeldungen und mehr als 100 wissenschaftliche Studien unterstützt. Die Herstellung erfolgt in zwei Einrichtungen in Costa Rica, die den ISO13485:2024- und FDA-Standards entsprechen.
- None.
- None.
Juan José Chacón-Quirós, Chief Executive Officer and Founder; Peter Caldini, President; and Raj Denhoy, Chief Financial Officer, are scheduled to present on Thursday, February 27, 2025 at 8:00 a.m. ET.
A live webcast of the presentation will be available on the Establishment Labs investor relations website at https://investors.establishmentlabs.com/. Archived versions of the webcasts will be available on the same website following the completion of the events.
About Establishment Labs
Establishment Labs Holdings Inc. is a global medical device company dedicated to improving women’s health and wellness in breast aesthetics and reconstruction through the power of science, engineering, and technology. The Company offers a portfolio of solutions for breast health, breast aesthetics, and breast reconstruction in over 90 countries. With over four million Motiva® devices delivered to plastic and reconstructive surgeons since 2010, the Company’s products have created a new standard for safety and patient satisfaction. The company’s minimally invasive platform consists of Mia Femtech®, a unique minimally invasive experience for breast harmonization, and Preservé™, a breast tissue preserving and minimally invasive technology for breast augmentation, revision augmentation and mastopexy augmentation. GEM® is a next generation minimally invasive system for gluteal ergonomic modeling currently undergoing an IRB approved pivotal study. The Motiva Flora® tissue expander is used to improve outcomes in breast reconstruction following breast cancer and is the only regulatory-approved expander in the world with an integrated port using radio-frequency technology that is MRI conditional. Zensor™ is an RFID technology platform used to safely identify implantable devices from outside the body, and includes the company’s first biosensor Zenº™, currently part of an IRB approved pivotal study to measure core breast temperature. These solutions are supported by over 200 patents applications in 20 separate patent families worldwide and over 100 scientific and clinical studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250221408159/en/
Investor/Media Contact:
Raj Denhoy
415 828-1044
rdenhoy@establishmentlabs.com
Source: Establishment Labs Holdings Inc.
FAQ
When is Establishment Labs (ESTA) presenting at Citi's 2025 Unplugged Medtech Conference?
How many Motiva devices has ESTA delivered since 2010?
What are the key products in ESTA's breast aesthetics portfolio?
How many countries does Establishment Labs (ESTA) operate in?
How many patents and clinical studies support ESTA's products?
Where are ESTA's manufacturing facilities located?
